Soluble P-selectin is the smoke, not the fire.

intermediary drives ibrutinib resistance, whereas presence of a complex karyotype and Del17p are predictive of progression while on ibrutinib. Additional work in larger cohorts of samples may be required to address whether USP7 inhibition would be sufficient to target disease in this subgroup of patients. In conclusion, despite unresolved queries, this study identifies that USP7 is an attractive therapeutic target in CLL and warrants its investigation both mechanistically and in clinical trials. Conflict-of-interest disclosure: The author declares no competing financial interests. n